CVS Health stock surged over 11% following a sizable revenue beat and the appointment of new CEO David Joyner. See why I'm ...

CVS Health fell short on third-quarter profit, but it posted strong sales and the health care giant shook up leadership under ...

Joyner’s comments were his first made publicly since he was promoted less than a month ago to replace Karen S. Lynch, who stepped down. CVS Health has struggled to control costs in its Aetna health ...

Taking into account the latest results, the current consensus from CVS Health's 23 analysts is for revenues of US$385.9b in ...

Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on CVS Health (CVS – Research Report). The associated price target was ...

Third-quarter adjusted earnings per share are $1.09, confirming preliminary numbers from October. A Trump victory is also ...

CVS Health (NYSE:CVS) traded ~6% higher in the premarket on Wednesday after the pharmacy chain operator reported ...

CVS Health rated Hold, offers dividend yield, facing challenges from CMS decisions and rising medical costs in healthcare sector. Learn more on CVS stock here.

CVS Health CEO David Joyner promoted an internal executive, Prem Shah, as company group president and hired from the outside, Steve Nelson, a former UnitedHealthcare CEO.

CVS Health (CVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Allen Lutz ...

In 2024, retail health care faced significant disruption as industry giants like Walgreens, CVS and Walmart reevaluated their ...